Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7207331 | 0.97 | TLR7 (0.70) | TLR7 | |
| SCHEMBL7205092 | 0.94 | TLR7 (0.66) | TLR7 | |
| SCHEMBL20764409 | 0.93 | TLR7 (0.65) | TLR7 | |
| SCHEMBL21449010 | 0.91 | TLR7 (0.62) | TLR7 | |
| SCHEMBL7209998 | 0.90 | TLR7 (0.61) | TLR7 | |
| SCHEMBL10174289 | 0.90 | TLR7 (0.64) | TLR7 | |
| SCHEMBL4465096 | 0.90 | TLR7 (0.68) | TLR7 | |
| SCHEMBL3689592 | 0.90 | TLR7 (0.63) | TLR7 | |
| SCHEMBL7205809 | 0.90 | TLR7 (0.61) | TLR7 | |
| SCHEMBL7205555 | 0.89 | TLR7 (0.60) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101340931-A | Modulation of tlr-mediated immune responses using adaptor oligonucleotides | COLEY PHARM GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| EP-1928500-A2 | MODULATION OF TLR-MEDIATED IMMUNE RESPONSES USING ADAPTOR OLIGONUCLEOTIDES | Coley Pharmaceutical GmbH (DE) | 2008-06-11 | — | — | EP | claimed |
| WO-2007038720-A2 | MODULATION OF TLR-MEDIATED IMMUNE RESPONSES USING ADAPTOR OLIGONUCLEOTIDES | COLEY PHARMACEUTICAL GMBH (DE) | 2007-04-05 | — | — | WO | claimed |
| US-11464854-B2 | Methods and compositions relating to adjuvants | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3668869-B1 | 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AS IMMUNOSTIMULANTS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3668870-B1 | 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS IMMUNOSTIMULANT TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3668868-B1 | TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A TRICYCLIC MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR | BRISTOL MYERS SQUIBB CO (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10981914-B2 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | Bristol-Myers Squibb Companay (US) | 2021-04-20 | — | — | US | disclosed |
| US-10941145-B2 | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-09 | — | — | US | disclosed |
| US-10927114-B2 | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-23 | — | — | US | disclosed |
| US-10919895-B2 | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-16 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| WO-2005025583-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1035123-B1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMA (JP) | 2003-08-20 | — | — | EP | disclosed |
| US-6329381-B1 | INTERFERONS, VIRICIDES AND ANTICARCINOGENIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1035123-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927114-B2 | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor | TLR7, TLR9, TLR1 | TLR7 1/4885 |
| US-10919895-B2 | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR4 | TLR7 1/4885 |
| US-10941145-B2 | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR4 | TLR7 1/4885 |
| US-10981914-B2 | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor | TLR7, TLR1, TLR4 | TLR7 1/4885 |
| US-11464854-B2 | Methods and compositions relating to adjuvants | TLR8, TLR7, TLR9 | TLR7 2/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | TLR7 31/4885 |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | TLR7, TLR3, TLR9 | TLR7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.